Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.
Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses the combination of enzalutamide (Xtandi) and docetaxel for the frontline treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
In the phase II CHEIRON study, patients with previously untreated mCRPC were randomized to 8 cycles of docetaxel every 3 weeks plus prednisone at 5 mg, or the same treatment plus enzalutamide at 160 mg daily for 24 weeks. Patients were stratified based on their pain level and visceral involvement. The primary endpoint of the study was progression-free survival (PFS), Caffo says.
According to data presented at the 2019 Genitourinary Cancers Symposium, the frontline combination led to a 6-month PFS rate of 89.1% compared with 72.8% in patients treated with docetaxel alone. At a median follow-up of 20 months, the median PFS was 10.1 months versus 9.1 months in favor of the combination (HR, 0.71; 95% CI, 0.54-0.94; P = .01). However, the combination was not shown to lead to a statistically significant improvement in overall survival.